[][com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=54011]], camposKey:1389-2029 2017-10-01 Optimization of antidepressant use with pharmacogenetic strategies442449, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=54012]], camposKey:1462-2416 2016-06-01 Pharmacogenetic considerations in the treatment of Alzheimer's disease10411074, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=54013]], camposKey:1871-5273 2016-03-01 Novel therapeutic strategies for dementia141241, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=54014]], camposKey:1381-6128 2016-02-01 Neuroimmune crosstalk in CNS disorders: The histamine connection819848, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=54015]], camposKey:0962-9351 2016-01-01 Histamine and immune biomarkers in CNS disorders00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=54016]], camposKey:1661-6596 2015-12-21 Epigenetics of aging and alzheimer¿s disease: Implications for pharmacogenomics and drug response3048330543, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=54092]], camposKey:1479-6708 2015-01-01 Opportunities in pharmacogenomics for the treatment of Alzheimer's disease229252, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=54017]], camposKey:1746-0441 2014-01-01 Epigenetic drug discovery for Alzheimer's disease10591086, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=54018]], camposKey:1878-3317 2014-01-01 Epigenomics of alzheimer's disease7582, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=54019]], camposKey:1064-3745 2014-01-01 Pharmacogenomics of alzheimer¿s disease: Novel therapeutic strategies for drug development323556, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=43499]], camposKey:0212-9728 2013-01-01 Influencia de la reserva cognitiva en la calidad de vida en sujetos con enfermedad de Alzheimer762771, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=43498]], camposKey:0210-0010 2011-01-01 Revisión del constructo deterioro cognitivo leve:: aspectos generales300305][CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19600]},camposKey: 585 617 Pharmacoepigenomics 0128032391Medical Epigenetics 1 2016-06-15 -, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19601]},camposKey: 65 256 Genomics, therapeutics and pharmacogenomics of attention- deficit/hyperactivity disorder 9781634831284Attention Deficit Hyperactivity Disorder (ADHD): Epidemiology, Treatment and Prevention 1 2015-07-01 -, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19602]},camposKey: 563 615 Personalized Medicine of Alzheimer's Disease 9780123868824Handbook of Pharmacogenomics and Stratified Medicine 1 2014-05-06 -][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][]